Pfizer (PFE) analyst forecast and price target
Analyst forecast
Consensus of 29 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Neutral | $30.00 from $28.00 | Oct 9, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $28.00 from $27.00 | Oct 8, 2026 |
| Scotiabank | Maintained | Sector Outperform | $33.00 from $30.00 | Oct 6, 2026 |
| HSBC | Maintained | Hold | $30.00 from $28.00 | Sep 10, 2026 |
| Guggenheim | Maintained | Buy | $31.00 from $35.00 | Aug 7, 2026 |
| Guggenheim | Maintained | Buy | $35.00 from $36.00 | Jul 13, 2026 |
| BMO Capital | Maintained | Outperform | $30.00 from $34.00 | Jul 13, 2026 |
| B of A Securities | Maintained | Neutral | $26.00 from $27.00 | Jul 10, 2026 |
| JP Morgan | Maintained | Neutral | $28.00 from $30.00 | Jul 8, 2026 |
| HSBC | Downgraded | Buy → Hold | $28.00 from $32.00 | Jul 6, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $27.00 | Jul 6, 2026 |
| RBC Capital | Upgraded | Underperform → Sector Perform | $25.00 | Jun 10, 2026 |
| Citigroup | Maintained | Neutral | $27.00 from $26.00 | Apr 29, 2026 |
| RBC Capital | Maintained | Underperform | $25.00 | Apr 20, 2026 |
| CICC | Initiated Coverage | Outperform | $33.00 | Apr 16, 2026 |
| UBS | Maintained | Neutral | $27.00 from $25.00 | Apr 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $28.00 from $27.00 | Apr 10, 2026 |
| B of A Securities | Maintained | Neutral | $26.00 from $27.00 | Apr 9, 2026 |
| Guggenheim | Maintained | Buy | $36.00 from $35.00 | Mar 24, 2026 |
| HSBC | Maintained | Buy | $32.00 from $29.00 | Mar 17, 2026 |
Frequently asked questions
What is the price target for PFE stock?
The average 12-month analyst price target for Pfizer (PFE) is $30.40, with a high estimate of $33.00 and a low of $28.00, across 5 analysts.
Is PFE a buy, sell, or hold?
Analysts covering Pfizer currently average a Hold rating: 9 buy, 18 hold and 2 sell, from 29 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PFE?
The average price target of $30.40 implies 4.07% upside from the last price of $29.21.
What is the latest analyst rating on PFE?
On Oct 9, 2026, JP Morgan maintained Pfizer at Neutral with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.